New research indicates that some cases of Alzheimer’s disease may involve infection by Porphyromonas gingivalis, a bacterial species that’s best known for causing gum disease in the mouth.
BY KATHERINE J. WU WEDNESDAY, JANUARY 23, 2019 NOVA WONDERS
As Alzheimer’s disease progresses, communication between brain cells breaks down. New research suggests that one possible cause for this deterioration may be a brain infection by Porphyromonas gingivalis, a bacterium known for causing gum disease. Image Credit: National Institute on Aging/NIH, flickr
A new treatment for Alzheimer’s disease might now be in the works—and it targets a microbe found in your mouth.
A study published today in the journal Science Advances pinpoints an unlikely villain in neurodegenerative disease: Porphyromonas gingivalis, a bacterium known to cause gum disease, might be capable of traversing the path from mouth to brain, where it can trigger chemical changes that damage cognitive function. These findings suggest that some cases of Alzheimer’s might have an infectious cause—and a new drug that blocks this process is now in clinical trials.
“This is very exciting in many ways,” says Sim Singhrao, who studies neurodegenerative disease at the University of Central Lancashire in the United Kingdom, but was not involved in the new study. “This work not only highlights the problem of poor oral hygiene as a risk factor for Alzheimer’s, but it might also offer a futuristic solution.”
P. gingivalis is best known for causing periodontitis, an inflammatory disease that steadily eats away at gums and bone that support teeth, due in part to this microbe’s production of gingipains, powerful enzymes that chew through other proteins. But in recent years, scientists have begun to tentatively link Alzheimer’s disease to P. gingivalisinfection—pointing to the possibility that these mouth-loving microbes might have the capacity to set up shop in the brain.
In the new study, a team led by Stephen Dominy and Casey Lynch of Cortexyme, a San Francisco-based company developing Alzheimer’s therapeutics, found bacterial gingipains in the brains of over 90 percent of a group of more than 50 deceased Alzheimer’s patients. And the more gingipains an individual had, the more that brain showed chemical signs of deterioration, including the accumulation of a protein called tau. Under normal circumstances, tau helps neurons maintain structural integrity. But in brains progressing toward Alzheimer’s, this protein can undergo abnormal chemical changes and tangle into knots inside brain cells, compromising their ability to send each other signals.
Porphyromonas gingivalis, a bacterial species that’s known to cause gum disease, might be capable of infiltrating the brain. Once there, its presence could trigger an immune response that ultimately compromises the function of brain cells. Image Credit: Airman 1st Class Dillian Bamman, U.S. Air Force
When the researchers introduced P. gingivalis into the mouths of eight mice, they found that the bacteria migrated into all of their brains within a few weeks. In response to the infection, the mice also seemed to be boosting production of a protein called amyloid beta. Like tau, amyloid beta occurs in the brain naturally but behaves abnormally in Alzheimer’s patients, forming sticky aggregates outside of cells.
What amyloid beta does under normal circumstances isn’t well understood. But some researchers, including Dominy and Lynch, believe that it plays a role in the immune system, and is manufactured when the body senses an unwanted microbe. “It’s kind of like the body sending out a little net, saying, ‘I’m going to trap these bacteria,’” Singhrao says.
While that might sound like a good thing, amyloid beta’s protective powers might ultimately cause harm. When P. gingivalis infiltrates the brain, amyloid beta could be cued into overdrive—and if these microbe-trapping nets aren’t cleared out of the way, they might glom together, clogging up lines of communication between brain cells. As with the case with tau, these cellular roadblocks could ultimately nudge the brain in the direction of dementia.
But Dominy believes there’s more to the issue than an overactive immune system. “We think the gingipains are really the culprit here,” he says. “They’re damaging the brain directly.”
In keeping with this, when the researchers exposed mice to a strain of P. gingivalis that lacked its destructive gingipains, the rodents suffered fewer Alzheimer’s-like changes in their brains. And when P. gingivalis-infected mice were treated with Cortexyme’s new anti-gingipain drug, fewer bacteria invaded the brain and there was less accumulation of amyloid beta.
Cortexyme’s drug is already in human clinical trials, and Lynch says the early results are encouraging. Regardless of the outcome for this particular drug, however, the case on Alzheimer’s is far from closed. Stronger links between oral infections and Alzheimer’s still need to be established in humans, says Allison Reiss, an Alzheimer’s researcher at New York University’s Winthrop Hospital who was not involved in the new study. After all, she says, while the study’s findings in mice are encouraging, what happens in rodents isn’t always recapitulated in humans.
Even if these results pan out in human populations, not all Alzheimer’s patients are the same, says Ming Guo, a neurologist and Alzheimer’s expert at the University of California, Los Angeles’ Brain Research Institute who was not involved